logo

Ascendis Pharma A/S (ASND)



Trade ASND now with
  Date
  Headline
4/4/2018 3:58:38 PM Wedbush Is Cutting Ascendis Pharma A/S (ASND) FY18 Estimate To -3.16 From -3.14
4/4/2018 3:58:20 PM Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q3 18 Estimate To -0.80 From -0.79
4/4/2018 3:56:22 PM Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $76 Up From $67 Price Target
3/28/2018 4:05:59 PM Ascendis Pharma A/S FY17 Loss/share EUR 3.68 Vs. Loss EUR 2.58 Year Ago
2/26/2018 1:19:52 PM Wedbush Is Increasing Ascendis Pharma A/S (ASND) 2018 Estimate To -3.14 From -3.53
2/26/2018 1:19:30 PM Wedbush Is Increasing Ascendis Pharma A/S (ASND) 4Q18 Estimate To -0.81 From -0.91
2/26/2018 1:19:11 PM Wedbush Is Raising Ascendis Pharma A/S (ASND) 3Q18 Estimate To -0.79 From -0.89
2/26/2018 1:18:48 PM Wedbush Is Raising Ascendis Pharma A/S (ASND) 2Q18 Estimate To -0.78 From -0.87
2/26/2018 1:18:30 PM Wedbush Is Raising Ascendis Pharma A/S (ASND) 1Q18 Estimate To -0.77 From -0.86
2/26/2018 1:16:10 PM Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $67 Price Target
2/21/2018 11:54:45 PM Ascendis Pharma Announces Pricing Of Public Offering Of 3.95 Mln ADSs At $57/ADS
2/6/2018 7:57:20 AM Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $62 Price Target
1/8/2018 8:28:54 AM Ascendis Updates On Rare Disease Endocrinology Pipeline And Presents Initial Phase 1 Data For TransCon PTH
11/29/2017 6:27:53 AM Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $62 Price Target
11/29/2017 6:26:54 AM Wedbush Is Lowering Ascendis Pharma A/S (ASND) 2018 Estimate To -3.53 From -2.81
11/29/2017 6:26:34 AM Wedbush Is Cutting Ascendis Pharma A/S (ASND) Q4 18 Estimate To -0.91 From -0.72
11/29/2017 6:26:21 AM Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q3 18 Estimate To -0.89 From -0.71